Health & Biotech
With M&A heating up in Aus cannabis, is it international land grab time?
Investors flocking to Melbourne for southern hemisphere’s biggest biotech investment conference
Cannabis: THC just got those long-awaited narcotics licenses
Building a sustainable biotech sector in WA
Health: the hits keep coming for Avecho Biotechnology
Check-up: Takeover bid puts workplace health solutions provider Konekt on top
600 prescriptions have now been written for MGC Pharma medicinal cannabis products
The life sciences investment wave is building. Here’s how to ride it.
The Health Kick Podcast with Tim Boreham: Anatara Lifesciences
Health: Roots’ cannabis-cooling tech might help boost crop yields by up to 118%
Health: Immutep gains 12% on promising melanoma treatment
Interview: Next Science chairman George Savvides on what’s in store for the bacteria-killing biotech
“We’re creating something the world doesn’t have”: Zelda boss on US merger
Health: Admedus shares fly 40pc on first trading day in six months
Dr Boreham’s Crucible: Recce Pharmaceuticals, the emerging superbug killer
Health: Oncosil stays hopeful with regulators, shares move higher
‘People want revenues and a genuine business’: how ASX pot stocks are maturing
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.
